Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Andrew Madin is active.

Publication


Featured researches published by Andrew Madin.


Chemistry & Biology | 2007

Apoptosis in T Cell Acute Lymphoblastic Leukemia Cells after Cell Cycle Arrest Induced by Pharmacological Inhibition of Notch Signaling

Huw D. Lewis; Matthew Leveridge; Peter Strack; Christine Haldon; Jennifer O'Neil; Hellen Kim; Andrew Madin; Joanne Clare Hannam; A. Thomas Look; Nancy E. Kohl; Giulio Draetta; Timothy Harrison; Julie Kerby; Mark S. Shearman; Dirk Beher


Archive | 1997

Substituted triazolo-pyridazine derivatives as ligands for GABA receptors

Howard B. Broughton; William Robert Carling; Jose Luis Castro Pineiro; Alexander Richard Guiblin; Andrew Madin; Kevin W. Moore; Michael Geoffrey Neil Russell; Leslie J. Street


Bioorganic & Medicinal Chemistry Letters | 2005

Cyclic sulfamide γ-secretase inhibitors

Tim Sparey; Dirk Beher; Jonathan D. Best; Mirlinda Biba; José L. Castro; Earl E. Clarke; Joanne Clare Hannam; Timothy Harrison; Huw D. Lewis; Andrew Madin; Mark S. Shearman; Bindi Sohal; Nancy N. Tsou; Christopher J. Welch; Jonathan D.J. Wrigley


Archive | 2001

Sulfamides as gamma-secretase inhibitors

Ian Collins; Joanne Claire Hannam; Timothy Harrison; Stephen John Lewis; Andrew Madin; Timothy Jason Sparey; Brian John Williams


Archive | 2001

Benzodiazepine derivatives as APP modulators

Jose Luis Castro Pineiro; Ian Churcher; Alexander Richard Guiblin; Timothy Harrison; Sonia Kerrard; Andrew Madin; Alan John Nadin; Andrew Pate Owens; Timothy Jason Sparey; Martin Richard Teall; Susannah Williams


Journal of Medicinal Chemistry | 2005

7-(1,1-dimethylethyl)-6-(2-ethyl-2h-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine : A functionally selective γ-aminobutyric AcidA (GABAA) α2/α3-subtype selective agonist that exhibits potent anxiolytic activity but is not sedating in animal models

Robert W. Carling; Andrew Madin; Alec Guiblin; Michael Geoffrey Neil Russell; Kevin William Moore; Andrew Mitchinson; Bindi Sohal; Andrew Pike; Susan M. Cook; Ian Ragan; Ruth M. McKernan; Kathleen Quirk; Pushpinder Ferris; George R. Marshall; Sally Ann Thompson; Keith A. Wafford; Gerard R. Dawson; John R. Atack; José L. Castro; Leslie J. Street


Archive | 2001

Sulphonamido-substituted bridged bicycloalkyl derivatives

Patrice Charles Belanger; Ian Collins; Joanne Claire Hannam; Stephen John Lewis; Andrew Madin; Iver Edward Giles Mc; Alan Nadin; Joseph George Neduvelil; Mark S. Shearman; Adrian Leonard Smith; Timothy Jason Sparey; Graeme Irvine Stevenson; Martin Richard Teall


Archive | 2003

Sulfonamides, sulfamates and sulfamides as gamma-secretase inhibitors

Andrew Madin; Mark Peter Ridgill


Archive | 1996

Azetidine, pyrrolidine and piperidine derivatives

Raymond Baker; Sylvie Bourrain; Jose Luis Castro Pineiro; Mark Stuart Chambers; Alexander Richard Guiblin; Sarah Christine Hobbs; Richard Alexander Jelley; Andrew Madin; Victor Giulio Matassa; Austin John Reeve; Michael Geoffrey Neil Russell; Graham A. Showell; Francine Sternfeld; Leslie J. Street; Monique Bodil Van Niel


Archive | 2007

Piperidines and related compounds for treatment of alzheimer's disease

Joanne Clare Hannam; Janusz Jozef Kulagowski; Andrew Madin; Mark Peter Ridgill; Eileen Mary Seward

Collaboration


Dive into the Andrew Madin's collaboration.

Researchain Logo
Decentralizing Knowledge